I would recommended that people read this announcement over again slowly before getting excited.
Don’t be misled by headline numbers.
This is just another research agreement with a long lead time before even the most preliminary and pre-clinical milestones could be achieved IMO.
As if Starpharma’s diverse and overflowing show bag of cheap tricks and crap candy wasn’t big enough, now we’re adding ‘investing’ in start-up companies rather than getting cash-flow licence fees.
Could be an opportunity to exit today for a profit if there is a short-term sugar hit to the share price.
I actually don’t like this announcement at all and it gives me even more cause for concern to be honest.
